Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
Shares of Novavax and Moderna fell after a market report said both companies had gained the prior session, when investors reacted to news of a suspected pneumonic plague case in Russia. Citi’s assessment of heightened volatility in the vaccine sector added to the pressure, according to the report.
THE APEX TIMES
THE APEX TIMES
A dividend comparison shared by TIKR says UnitedHealth increased its annual per-share dividend to $9.28, while CVS continues to pay $2, sharpening the focus on income stability across large U.S. health insurers.
THE APEX TIMES
The drugmaker said it raised revenue guidance for the second quarter of 2026, held earnings guidance unchanged, and outlined another round of cost cuts, even as it posted a loss of 4 cents per share.
THE APEX TIMES
A market pullback saw healthcare stand out as one of the few areas that held up, with Moderna and Eli Lilly among the names moving higher in the session covered by Yahoo Finance.
THE APEX TIMES
CVS Health (NYSE: CVS) climbed to $87.95 on Oct. 7, moving higher even as the market reportedly declined.
THE APEX TIMES
A recent market discussion frames Johnson & Johnson as shifting from a purely defensive healthcare holding toward a more growth-oriented profile, while questioning whether the market is paying too much relative to AbbVie.
THE APEX TIMES
A Yahoo Finance analysis points to Pfizer’s forward price-to-earnings (P/E) trading below 10x, and contrasts that with Johnson & Johnson’s higher valuation, framing the gap as largely tied to differences in each company’s earnings outlook rather than current earnings alone.
THE APEX TIMES
A new joint venture involving Solis Mammography and HCA Healthcare’s Trident Hospital is bringing expanded breast imaging services to Charleston, while Solis operations are being repositioned under the Solis banner with additional rollouts planned.
THE APEX TIMES
A new market commentary framed Pfizer’s stock decision around the possibility of a tougher operating period ahead, while noting that investors will likely weigh valuation against near-term uncertainties.
